Share Name Share Symbol Market Type Share ISIN Share Description
Batm Advanced Communications Ld LSE:BVC London Ordinary Share IL0010849045 ORD ILS0.01
  Price Change % Change Share Price Shares Traded Last Trade
  0.80 1.81% 45.00 465,316 16:15:03
Bid Price Offer Price High Price Low Price Open Price
44.70 45.00 45.90 44.00 44.40
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Technology Hardware & Equipment 93.75 0.95 0.07 650.9 198
Last Trade Time Trade Type Trade Size Trade Price Currency
16:35:18 UT 22,008 45.00 GBX

Batm Advanced Communicat... (BVC) Latest News

More Batm Advanced Communicat... News
Batm Advanced Communicat... Takeover Rumours

Batm Advanced Communicat... (BVC) Discussions and Chat

Batm Advanced Communicat... Forums and Chat

Date Time Title Posts
17/1/202016:18Batm Advanced - A New Beginning15,945
30/8/201616:01BATM - Broadband bright future22,405
09/8/201321:00batm great trading statement41
21/11/201120:58BATM * BATM * BATM * BATM ******BUNG A ROCKET IN YER PORTFILIOS45
14/5/201119:07SHARE TIP OF THE DECADE79

Add a New Thread

Batm Advanced Communicat... (BVC) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
2020-01-17 16:35:1845.0022,0089,903.60UT
2020-01-17 16:25:0645.001,005452.25AT
2020-01-17 16:21:5445.0021898.10AT
2020-01-17 16:15:0345.002,6271,182.15AT
2020-01-17 16:05:4144.80924413.95AT
View all Batm Advanced Communicat... trades in real-time

Batm Advanced Communicat... (BVC) Top Chat Posts

DateSubject
18/1/2020
08:20
Batm Advanced Communicat... Daily Update: Batm Advanced Communications Ld is listed in the Technology Hardware & Equipment sector of the London Stock Exchange with ticker BVC. The last closing price for Batm Advanced Communicat... was 44.20p.
Batm Advanced Communications Ld has a 4 week average price of 36p and a 12 week average price of 36p.
The 1 year high share price is 54p while the 1 year low share price is currently 36p.
There are currently 440,279,074 shares in issue and the average daily traded volume is 580,074 shares. The market capitalisation of Batm Advanced Communications Ld is £198,125,583.30.
31/12/2019
14:38
fse: Happy New Year all. Difficult year ahead with a recession thats been looming for some time now and does explain "some" of the recent weakness. Tech stock always get impacted ahead of any general set back. In any event the value of BATM IP is not reflected in the current share price, we are further down the road to seeing meaningful revenue from the new technologies.
30/12/2019
21:46
gbenson1: You can see the short trades every day in this stock, heaven knows why they picked BVC, but I guess they see it as a way of making a few bob, the share price until more recently had been on a good run from 25-52p, bring back the time when people invested because they wanted to see companies doing well and prospering!!
19/12/2019
17:32
car1pet: Stesh That is an end of day "uncrossed trade". There is an algorithm to calculate it. It doesn't necessarily mean that will be the opening price tomorrow. The share price has been hovering around 40p recently. I expect it to continue unless there is some negative news out there. It would be helpful if there was some positive news but no sign at the moment.
09/12/2019
09:48
car1pet: Looks like same old BATM. Full of promises for the future but never materialise into growth in business and share price. After 10 years holding I think I will sell out in January. I'll wait to see if there is santa rally!!
09/10/2019
11:23
car1pet: At the moment the market doesn't see the future. Maybe things will change but when you 've held shares as long as I have cynicism overules. I keep saying the same thing Marom is not the right man to run this company as a business. By all means keep him on in a research role but get a commercial person to drive it forward. The share price would leap if they appointed a well known respected person who has a successful track record in running a tech business.
02/10/2019
08:03
reeltime: Finished the JDA ahead of schedule with Arm, proof of concepts underway with several network operators.......good timing with 5G upon us, upwards and on-wards. BATM Advanced Communications Ld BATM completes delivery under Arm agreement 02/10/2019 7:00am UK Regulatory (RNS & others) RNS Number : 4287O 2 October 2019 BATM Advanced Communications Limited ("BATM" or "the Group") BATM completes delivery under Arm(R) agreement Negotiations underway for proof-of-concept and trials with several network operators BATM (LSE: BVC; TASE: BVC), a leading provider of real-time technologies for networking solutions and medical laboratory systems, announces the completion of delivery under its joint development agreement ("JDA") with Arm to develop the Group's NFVTime operating system to enable an ecosystem of Virtual Network Function ("VNF") services optimised to run on Arm's architecture. Negotiations are now underway with network operators to undertake proof-of-concept of the joint network function virtualisation ("NFV") solution. The Group's NFVTime operating system is integrated with Arm technology to be used on Arm-based uCPE related SoCs (system-on-a-chip). The parties have been conducting joint marketing of the solution that enables carriers to deploy their own virtualised networks, which can also be a key element in allowing operators to leverage the benefits offered by 5G. Following the achievement by the Group of the milestones under the JDA, which had been scheduled to complete by year end, negotiations are now underway with several network operators in the US and Europe to undertake proof-of-concept, which, if successful, would be followed by field trials ahead of full deployment. Dr Zvi Marom, Chief Executive Officer of BATM, said: "We are delighted to have delivered the milestones under our strategic agreement with Arm and to have achieved this ahead of schedule. Our NFV ecosystem is designed to support an entirely virtualised network infrastructure, which will also be central to the implementation of 5G technologies and running applications such as to enable the Internet of Things. We are also extremely proud to have been chosen by Arm as their partner, which is testimony to the strength of our solution. With negotiations underway with network operators to conduct proof-of-concept trials, we are excited for the future prospects of this partnership and our NFV solution and believe the market opportunity is significant." Enquiries: BATM Advanced Communications Dr Zvi Marom, Chief Executive Officer +972 9866 2525 Moti Nagar, Chief Financial Officer Shore Capital Mark Percy, Anita Ghanekar, James Thomas +44 20 7408 4050 Luther Pendragon Harry Chathli, Claire Norbury, Joe Quinlan +44 20 7618 9100 This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com. END hTTps://uk.advfn.com/stock-market/london/batm-advanced-communicat-BVC/share-news/BATM-Advanced-Communications-Ld-BATM-completes-del/80843667
18/9/2019
08:52
cumnor: Mr Nagar's share sale, both the amount and manner (no mention of reason-not that its required but given his position a hint could have helped allay fears) has certainly put an added damper on BVC's share price of late. Not sure what the rest of the BOD think.
22/8/2019
11:37
reeltime: Just spotted this...very positive article from Simon Thompson IC. Exploit BATM’s hidden value Simon Thompson Simon Thompson I have had an enlightening results call with the directors of BATM Advanced Communications (BVC:45p), a provider of medical laboratory systems, cyber security and network solutions with extensive operations in Israel. The £197m market capitalisation company is celebrating its twentieth anniversary on the main list of the London Stock Exchange. It’s shaping up to be a vintage one, too, as analysts at house broker Shore Capital predict that BATM’s full-year adjusted pre-tax profits are set to more than treble from $2m to $6.7m (£5.5m). This is partly driven by a forecast $8m increase in revenue to $128m, but also by gains on investments in joint ventures, highlighting the hidden value in the company’s balance sheet. For instance, at the start of the year, BATM secured a $30m (£24.8m) investment from new investors to provide the funding for the commercialisation of its molecular biology diagnostics joint venture business, Ador Diagnostics, a company that is developing a new molecular diagnostic bench-top analyser that is able to probe 100 targets in a single proprietary carbon array. Existing products only probe on average between four and six targets per test sample. It is being targeted at screening for hospital-acquired infections such as MRSA and C. Diff, and to identify tropical infections in travellers returning home with fevers. BATM’s retained 38.2 per cent stake in Ador is worth $17.2m, a hefty sum in relation to BATM’s $4m investment prior to the $14.5m initial investment by the new investors. Furthermore, an additional $15.5m at a valuation a third higher than Ador’s current enterprise valuation of $45m will be funded by the same new investors at the end of 2020, subject to certain milestones being achieved. Bearing this in mind, BATM chief executive Zvi Marom says that the meningitis cartridges have already gained CE approval, and the bench-top analyser machines are likely to gain CE approval in the coming months, ahead of in-hospital testing and full commercialisation of the product. The point being that BATM has only booked a $3.2m gain on its Ador investment, and carries all investments in associates and joint ventures at just $9.4m on its balance sheet. The retained 38 per cent stake in Ador is worth almost double this sum alone, and that doesn’t factor in a likely sharp increase in the value of the stake when commercial quantities of the diagnostic bench-top analyser and cartridges are shipped in 2021. Tapping into 5G potential There are exciting prospects in 5G, too, as BATM’s network and cyber security division is accelerating the network function virtualisation (NFV) ecosystem project that it is developing in partnership with the world’s leading chip designer, Softbank-owned Arm Holdings, as the only worldwide software vendor to provide NFV functionality to Arm and Intel platforms. The partnership is developing infrastructure solutions for NFV, a technology that decouples the network functions, such as firewalling, intrusion detection and caching from proprietary hardware appliances, so they can run in software. The technology will be critical in the functionality of mobile applications in 5G and can also be used to run applications such as autonomous vehicles. Dr Marom notes that Arm Holdings could be ready to sell the technology to its customers shortly and is “planning some very large proof of concept 5G trials.” The point being that having made its investment in NFV technology, and integrated it into products of major chip makers including NXP Semiconductors (US:NXPI), a $34bn market capitalisation company listed on the New York Stock Exchange, then BATM is incredibly well placed to reap the rewards as consumer demand for 5G really takes off. Moreover, network operators and virtualised network function providers will be able to deploy their applications and operate across all major hardware architectures, so leveraging the advancements in different processor technologies. It’s well worth noting that analysts at Shore Capital have not included any contribution from NFV sales in their 2020 revenue estimate of $137m, nor in their 2021 revenue estimate of $148m when they predict BATM will be making pre-tax profit of $9.4m. Both forecasts also exclude any contribution from Ador, too, thus highlighting scope for outperformance. I would also flag up that BATM’s network and cyber security business is set for a storming second half, and beyond. Finance director expects the division to report annual revenues of $61.5m, up from $57.5m in 2018, and at similar margin, thus offering scope to increase the unit’s adjusted operating profit of $5.5m. Please note the 2018 profit has been restated due to new accounting standard IFRS16. Of course, BATM will be absorbing short term losses on some joint ventures as the businesses develop, too. For instance, the $3.2m gain on the Ador investment will be halved once you take into account BATM’s 38 per cent share of Ador’s losses this year, but this is already factored into the aforementioned analyst profit forecasts. Creating shareholder value What’s clear to me is that BATM is in the process of creating significant value for shareholders through its joint ventures, and potentially a multi-million dollar royalty stream from its partnership with Arm Holdings. That’s not in the price which is why having first advised buying BATM’s shares, at 19.25p, in my 2017 Bargain Shares Portfolio, and top-sliced half the holding, at 50p, to bank a 159 per cent partial gain (‘Bargain Shares: Exploiting pricing anomalies and top-slicing’, 3 Dec 2018), I subsequently advised reinvesting the proceeds from that share disposal to take advantage of a repeat buying opportunity, at 43.5p, earlier in the summer (‘BATM armed for a re-rating’, 11 Jul 2019). I feel that my sum-of-the-parts valuation of 60p is a very realistic target to value the company’s equity at £262m, or treble the last reported net asset value of $100m after taking into account last month’s $17m (£14m) equity raise at 42.5p, details of which I covered in some detail in my last article. That’s because BATM now has net cash of $34.6m (£28.5m); the retained stake in Ador is worth £17.2m and could easily be worth double that valuation by the end of 2020; BATM’s 95 per cent stake in Adaltis, an Italian manufacturer of medical diagnostics equipment has a read-through valuation of £45m; and BATM owns conservatively valued property assets worth $16m (£13.2m). Furthermore, even if you value BATM’s networking and cyber security division on 16 times last year’s operating profit then it’s still worth around $90m (£74m) as a standalone entity. Add to that the value embedded in the Arm Holdings partnership, and the rest of BATM’s biomedical division, too, and it’s really not difficult to arrive at a 60p sum-of-the-parts valuation. Fund manager Lombard Odier Asset Management clearly sees the investment potential as BATM’s largest shareholder has just purchased 4.3m shares to lift its stake to 26.04 per cent of the 437m shares in issue. Importantly, there is ample scope for positive news flow in the coming months to focus investors’ mind on BATM’s hidden balance sheet value, and the exciting commercial potential of its technology investments. A return to the April 2019 10-year share price high of 54p, and beyond looks a distinct possibility. Strong buy.
13/7/2019
15:24
fse: This report from Simon Thompson is now in the public domain so have copied it below. FWIW I would concurr with Simon's observations. Its an excellent summary of where the company is now and its near term future. The current share price only partially reflects the value of the company's IP. hTTps://cms.investorschronicle.co.uk/comment/2019/07/11/batm-armed-for-a-re-rating/ Simon Thompson July 11, 2019 BATM armed for a re-rating Simon Thompson Simon Thompson Shares in BATM Advanced Communications (BVC:43.5p), a provider of medical laboratory systems and cybersecurity and network solutions with extensive operations in Israel, started trading on the Tel Aviv Stock Exchange today, exactly 20 years after the company joined the Main List of the London Stock Exchange. BATM will retain its primary London listing and shares on both the Tel Avi and London Stock Exchanges will be fully transferrable. Based on 438m shares in issue, BATM has a market capitalisation of £192m, so it expects to become a constituent of the TA-90 index which tracks the 90 shares with the highest market capitalisation that are not included in the TA-35 index. The secondary listing will provide a local trading platform for the Israeli-based institutions that recently became shareholders after BATM raised $18m (£14.1m) in a placing at 42.5p a share at the end of June. It will also expand the accessibility of the shares to a wider pool of investors and increase the breadth and depth of the company’s shareholder base, with the aim of improving the liquidity and tradability of the shares. That can only be positive for BATM’s share price. It’s worth noting that the company raised $3m more than the $15m minimum amount it was seeking in the placing, highlighting strong investor demand. Profit from network function virtualisation That’s understandable given that the proceeds of the fundraise will be primarily used in BATM’s network and cyber security division to fund an acceleration of the network function virtualisation (NFV) ecosystem projects that BATM is developing in partnership with the world’s leading chip designer, Softbank-owned Arm Holdings, as the only worldwide software vendor to provide NFV functionality to Arm and Intel platforms. The exciting partnership is developing infrastructure solutions for NFV, a technology that decouples the network functions, such as firewalling, intrusion detection and caching from proprietary hardware appliances, so they can run in software. The solution is being integrated into the products of major chip makers, including NXP Semiconductors (NSQ:NXPI), a US$31bn market capitalisation company listed on the New York Stock Exchange. The technology could be a real money-spinner for both BATM and Arm holdings given that NFV is going to play a critical role in supporting the services 5G network operators will be able to offer. It can also be used to run applications such as autonomous vehicles. Moreover, network operators and virtualised network function providers will be able to deploy their applications and operate across all major hardware architectures, so leveraging the advancements in different processor technologies. BATM has conducted successful proof-of-concept trials with tier 1 and 2 telecom operators. The royalty stream from major network operators adopting the JDA’s technology could easily run into millions of dollars. It’s also worth noting that BATM has already launched a new technology under its long-standing partnership with NXP to enable a significant increase in network traffic, without requiring an increase in computing power, when licensing the company’s NFVTime operating system on certain NXP processors built on Arm core technology. In addition, BATM has entered into a strategic technology partnership with Clavister (STO:CLAV), a Sweden-based network security vendor of high-performance cybersecurity solutions, to run its Arm-optimised virtualised cybersecurity platform on NFVTime. Some of the funds raised from the placing will be used to complete development of BATM’s CyberGuard security product for NFV use cases. With a heavy weight partner in Arm Holdings on board, it goes without saying that BATM is strategically incredibly well-placed to benefit as network functions become increasingly virtualised. Molecular diagnostics: a growth opportunity The other major growth opportunity for BATM is in its molecular biology diagnostics joint venture business, Ador Diagnostics, a company that is developing a new molecular diagnostic bench-top analyser that is able to probe 100 targets in a single proprietary carbon array. Existing products only probe on average between four and six targets per test sample. It is being targeted at screening for hospital-acquired infections such as MRSA and C. Diff, and to identify tropical infections in travellers returning home with fevers. Earlier this year, Ador secured a $30m (£24m) investment from new investors to provide the funding for the commercialisation of the product in 2020. The initial $14.5m investment was received in April which placed a an enterprise value of $44.5m on Ador, implying BATM’s retained 38.2 per cent stake in the joint venture is worth $17m. Moreover, a further $15.5m (at a valuation that will be 33.3 per cent higher than the current enterprise valuation) will be funded by the same new investors at the end of 2020, subject to certain milestones being achieved, highlighting clear potential for even more value creation for BATM’s shareholders. Around 10 per cent of BATM’s recent equity raise will be used to accelerate development, deployment and certifications (including patents) in BATM’s molecular biology diagnostics business, and for its ground breaking agri-waste and pharma-waste treatment subsidiaries. This is a very sensible move. Hidden balance sheet value It’s well worth pointing out that BATM’s retained stake in Ador is held in BATM’s balance sheet at a fraction of its read through valuation as is the company’s 95 per cent stake in Adaltis, an Italian manufacturer of medical diagnostics equipment that has a read through valuation of £45m. BATM had $18.5m (£14.8m) of net cash and conservatively valued property assets worth $16m (£12.8m) at the start of 2019, too. BATM’s cyber security division is clearly very valuable, too, as a standalone venture. The business has been winning a raft of contracts, one reason it quadrupled operating profit to $3.6m on 16 per cent higher revenues of $57.5m in 2018.
26/6/2019
09:14
miti 1000: I imagine that volsung only likes share prices to go up all the time. In reality, nothing much has changed apart from the share price falling after a strong run. BVC have always made it clear that networking revenues from ARM partners won't really flow thru till mid/late 2020 so nice to see them raise capital to advance that opportunity. The only surprise is that they chose to raise so little imo.
Batm Advanced Communicat... share price data is direct from the London Stock Exchange
Your Recent History
LSE
BVC
Batm Advan..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20200118 08:48:26